CN101133017A - 放射性卤素标记的苯氧基苯胺衍生物 - Google Patents
放射性卤素标记的苯氧基苯胺衍生物 Download PDFInfo
- Publication number
- CN101133017A CN101133017A CNA2005800488048A CN200580048804A CN101133017A CN 101133017 A CN101133017 A CN 101133017A CN A2005800488048 A CNA2005800488048 A CN A2005800488048A CN 200580048804 A CN200580048804 A CN 200580048804A CN 101133017 A CN101133017 A CN 101133017A
- Authority
- CN
- China
- Prior art keywords
- atom
- carbon atom
- representative
- halogen
- alkoxyl group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002285 radioactive effect Effects 0.000 title claims abstract description 20
- 229910052736 halogen Inorganic materials 0.000 title claims abstract description 16
- 150000002367 halogens Chemical class 0.000 title claims abstract description 16
- GYNAVKULVOETAD-UHFFFAOYSA-N n-phenoxyaniline Chemical class C=1C=CC=CC=1NOC1=CC=CC=C1 GYNAVKULVOETAD-UHFFFAOYSA-N 0.000 title description 2
- 125000005843 halogen group Chemical group 0.000 claims abstract description 30
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 20
- 201000010099 disease Diseases 0.000 claims abstract description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 18
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 16
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 15
- -1 formamyl Chemical group 0.000 claims description 63
- 229910052799 carbon Inorganic materials 0.000 claims description 44
- 125000004432 carbon atom Chemical group C* 0.000 claims description 41
- QZVCTJOXCFMACW-UHFFFAOYSA-N Phenoxybenzamine Chemical class C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1 QZVCTJOXCFMACW-UHFFFAOYSA-N 0.000 claims description 13
- 208000018737 Parkinson disease Diseases 0.000 claims description 11
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 206010003571 Astrocytoma Diseases 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 206010012289 Dementia Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 201000009906 Meningitis Diseases 0.000 claims description 5
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 208000010886 Peripheral nerve injury Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
- 206010014599 encephalitis Diseases 0.000 claims description 5
- 206010015037 epilepsy Diseases 0.000 claims description 5
- 239000005556 hormone Substances 0.000 claims description 5
- 229940088597 hormone Drugs 0.000 claims description 5
- 201000007270 liver cancer Diseases 0.000 claims description 5
- 208000014018 liver neoplasm Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 5
- 208000029974 neurofibrosarcoma Diseases 0.000 claims description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
- 201000000498 stomach carcinoma Diseases 0.000 claims description 5
- 210000003478 temporal lobe Anatomy 0.000 claims description 5
- 231100000216 vascular lesion Toxicity 0.000 claims description 5
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 201000005179 adrenal carcinoma Diseases 0.000 claims description 4
- 201000005188 adrenal gland cancer Diseases 0.000 claims description 4
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 4
- 208000005017 glioblastoma Diseases 0.000 claims description 4
- 201000002313 intestinal cancer Diseases 0.000 claims description 4
- 208000025189 neoplasm of testis Diseases 0.000 claims description 4
- 208000012991 uterine carcinoma Diseases 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 abstract description 13
- 238000005259 measurement Methods 0.000 abstract description 4
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 3
- 238000002603 single-photon emission computed tomography Methods 0.000 abstract description 3
- 239000003446 ligand Substances 0.000 abstract 2
- 238000000338 in vitro Methods 0.000 abstract 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 210000004556 brain Anatomy 0.000 description 10
- 239000000460 chlorine Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 229940049706 benzodiazepine Drugs 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- DCRZYADKQRHHSF-UHFFFAOYSA-N daa-1106 Chemical compound COC1=CC=C(OC)C(CN(C(C)=O)C=2C(=CC=C(F)C=2)OC=2C=CC=CC=2)=C1 DCRZYADKQRHHSF-UHFFFAOYSA-N 0.000 description 5
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000002600 positron emission tomography Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 150000001557 benzodiazepines Chemical class 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- UKLDJPRMSDWDSL-UHFFFAOYSA-L [dibutyl(dodecanoyloxy)stannyl] dodecanoate Chemical class CCCCCCCCCCCC(=O)O[Sn](CCCC)(CCCC)OC(=O)CCCCCCCCCCC UKLDJPRMSDWDSL-UHFFFAOYSA-L 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 210000001638 cerebellum Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000002987 choroid plexus Anatomy 0.000 description 2
- CGUBOFYHGYNUDL-UHFFFAOYSA-N daa-1097 Chemical compound CC(C)OC1=CC=CC=C1CN(C(C)=O)C1=CC=C(Cl)C=C1OC1=CC=CC=C1 CGUBOFYHGYNUDL-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 210000000956 olfactory bulb Anatomy 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- UEMGWPRHOOEKTA-UHFFFAOYSA-N 1,3-difluorobenzene Chemical compound FC1=CC=CC(F)=C1 UEMGWPRHOOEKTA-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- ZYHQGITXIJDDKC-UHFFFAOYSA-N 2-[2-(2-aminophenyl)ethyl]aniline Chemical group NC1=CC=CC=C1CCC1=CC=CC=C1N ZYHQGITXIJDDKC-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- CIXFKWAYMMHFFR-UHFFFAOYSA-N CCCCCCOC(C(C1CC1)(C(C(CCC)OC(C)C)(OCCCC)OCC(C)C)OC)(OCCCCC)OCCC(C)C.[O] Chemical compound CCCCCCOC(C(C1CC1)(C(C(CCC)OC(C)C)(OCCCC)OCC(C)C)OC)(OCCCCC)OCCC(C)C.[O] CIXFKWAYMMHFFR-UHFFFAOYSA-N 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 208000012601 choreatic disease Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000002898 ectopic hormone Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000004508 fractional distillation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 201000010256 myopathy, lactic acidosis, and sideroblastic anemia Diseases 0.000 description 1
- HPBYTOFDSULWOO-UHFFFAOYSA-N n-(5-fluoro-2-phenoxyphenyl)acetamide Chemical compound CC(=O)NC1=CC(F)=CC=C1OC1=CC=CC=C1 HPBYTOFDSULWOO-UHFFFAOYSA-N 0.000 description 1
- NZVKWLWAFUSDQE-FNNGWQQSSA-N n-[[2-(2-fluoranylethoxy)-5-methoxyphenyl]methyl]-n-(5-fluoro-2-phenoxyphenyl)acetamide Chemical compound COC1=CC=C(OCC[18F])C(CN(C(C)=O)C=2C(=CC=C(F)C=2)OC=2C=CC=CC=2)=C1 NZVKWLWAFUSDQE-FNNGWQQSSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005447 octyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- CFHIDWOYWUOIHU-UHFFFAOYSA-N oxomethyl Chemical compound O=[CH] CFHIDWOYWUOIHU-UHFFFAOYSA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960003418 phenoxybenzamine Drugs 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/001—Acyclic or carbocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C233/04—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C233/07—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/88—Carboxylic acid amides having nitrogen atoms of carboxamide groups bound to an acyclic carbon atom and to a carbon atom of a six-membered aromatic ring wherein at least one ortho-hydrogen atom has been replaced
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
一种右式所示的放射性卤素标记的苯氧基苯胺衍生物，其中，R1代表的基团如烷基；X1、X2、X3和X4各自代表氢原子、烷基、烷氧基、其中导入有11C或携带了放射性卤原子的烷氧基，其条件是X1、X2、X3和X4中的至少一个代表其中导入了11C或携带了放射性卤原子的烷氧基；该化合物可用作具有很高亲和力和很高选择性的PBR配体。在PBR的体外测定中，将具有很高亲和力和很高的选择性的PBR配体用放射性卤素核素进行标记，以便能够使用包括PET以及SPECT的工具在体内测定PBR。因此，可以得到用于疾病如阿尔茨海默型痴呆症的早期诊断、预防和治疗的化合物。
Description
技术领域
本发明涉及对外周苯二氮卓类受体具有很高亲和性的放射性卤素标记的苯氧基苯胺(phenyloxyaniline)衍生物。
背景技术
苯二氮卓类受体(BZ)分为中枢和外周受体。首先在外周组织中观察到了苯二氮卓类受体(PBR)，但在中枢神经系统中也识别到了其存在。而且，已经揭示出，PBR在中枢神经系统中的密度很高，几乎与中枢苯二氮卓类受体(CBR)在相同区域中的密度一样高或者更高。迄今的研究报道，PBR与多种疾病相关，这些疾病如阿尔茨海默氏病(Alzheimer’s disease)、额颞叶痴呆症(front-temporal dementia)、弥漫性Lewy小体病(diffuse Lewy corpuscle disease)、血管病变、帕金森氏症(Parkinson’s disease)相关疾病、皮质延髓变性(corticobasilardegeneration)、帕金森氏症、惠廷顿氏舞蹈病(Huntington’s chorea)、多系统萎缩症、多发性硬化、癫痫症、脑膜炎、脑炎、外周神经损伤、喉癌、乳癌、卵巢肿瘤、肝癌、大肠癌、胃癌、肾上腺癌、神经胶质瘤、成胶质细胞瘤、成纤维细胞瘤、神经肉瘤、肺癌、子宫癌、淋巴瘤、前列腺癌、黑素瘤、睾丸肿瘤、星形细胞瘤、异位产生激素的肿瘤(ectopic hormone-producing tumor)。
在用正电子发射断层显像(PET)对活体人脑的脑内PBR分布进行成像时，使用常规的PBR配体11C-标记的N-甲基-N-(1-甲基丙基)-1-(2-氯苯基)-异喹啉-3-羧酰胺(下文中称作“PK 11195)来诊断脑神经胶质瘤和阿尔茨海默氏症。但由于该化合物在脑中的积累极少，并且在定量分析方面存在问题，需要开发出能给予很高信号的PBR配体。在此情况下，现在清楚的是，N-(2，5-二甲氧基苄基)-N-(5-氟-2-苯氧基苯基)乙酰胺(下文中称作DAA1106)和N-(2-氟代甲基-5-甲氧基苄基)-N-(5-氟-2-苯氧基苯基)乙酰胺(下文中称作FMDAA1106)[专利文件2]和N-[2[(2-氟)乙基-5-甲氧基苄基]-N-(5-氟-2-苯氧基苯基)乙酰胺(下文中称作FEDAA1103)[专利文件2]均具有很强的亲和性和很高的选择性，因此它们非常适合于此用途。即，用11C标记的[11C]DAA1106，以及用18F标记的[18F]FMDAA1106和[18F]FEDAA1106作为PET示踪剂在脑内PBR的外部计数中均能给出很高的信号，这在定量分析中是高度准确的。
专利文件1：JP 11-171844A
专利文件2：JP 2004-231647A
发明内容
本发明的目的是提供用作PBR配体的具有很强亲和性和很高选择性的化合物，以及能够通过在PBR的外部计数中用放射性卤素核素对具有很强亲和性和很高选择性的PBR配体进行标记，通过包括PET以及SPECT的技术测定活体内的PBR。
为解决上述问题，本发明人进行了广泛的研究，从而发现，通过改变JP 11-171844A中所述的化合物的烷基成为卤代烷基，可以实现优异的PBR亲和力，从而完成本发明。
即，本发明涉及一种式(I)所示的放射性卤素标记的苯氧基苯胺衍生物
[式1]
其中，R1代表氢原子、具有1-10个碳原子的取代或未取代烷基、具有1-10个碳原子的烷氧基、取代或未取代苯基、式-NR2(R3)所示的基团，其中R2和R3相同或者不同，并代表氢原子、具有1-10个碳原子的取代或未取代烷基，或者与相邻的氮原子一起形成4-10元环状氨基，且X1、X2、X3和X4相同或不同，各自代表氢原子、具有1-5个碳原子的烷基、具有1-5个碳原子的烷氧基、苯氧基、三氟甲基、氨基甲酰基、氨基磺酰基、卤原子或选自121I、123I、124I、125I、131I、75Br、76Br、77Br和34mCl的放射性卤原子，其条件是X1、X2、X3和X4中的至少一个代表选自121I、123I、124I、125I、131I、75Br、76Br、77Br和34mCl的放射性卤原子。
优选地，本发明涉及一种根据权利要求1所述的放射性卤素标记的苯氧基苯胺衍生物，其中，R1代表氢原子、具有1-10个碳原子的取代或未取代烷基，且X1、X2、X3和X4相同或不同，各自代表氢原子、具有1-5个碳原子的烷氧基、卤原子或选自121I、123I、124I、125I、131I、75Br、76Br、77Br和34mCl的放射性卤原子，其条件是X1、X2、X3和X4中的至少一个代表选自121I、123I、124I、125I、131I、75Br、76Br、77Br和34mCl的放射性卤原子。
更优选地，本发明涉及一种根据权利要求1所述的放射性卤素标记的苯氧基苯胺衍生物，其中，R1代表具有1-10个碳原子的取代或未取代烷基，X1和X2各自代表具有1-5个碳原子的烷氧基，X3代表选自121I、123I、124I、125I、131I、75Br、76Br、77Br和34mCl的放射性卤原子，且X4代表氢原子。
最优选地，本发明涉及一种根据权利要求1所述的放射性卤素标记的苯氧基苯胺衍生物，其中，R1代表具有1-10个碳原子的取代或未取代烷基，X1和X2相同或不同，各自代表具有1-5个碳原子的烷氧基或选自121I、123I、124I、125I、131I、75Br、76Br、77Br和34mCl的放射性卤原子，其条件是X1和X2中的任一个代表选自121I、123I、124I、125I、131I、75Br、76Br、77Br和34mCl的放射性卤原子，X3代表卤原子，且X4代表氢原子。
此外，本发明涉及阿尔茨海默氏病、额颞叶痴呆症、弥漫性Lewy小体病、血管病变、帕金森氏症相关疾病、皮质延髓变性、帕金森氏症、惠廷顿氏舞蹈病、多系统萎缩症、多发性硬化、癫痫症、脑膜炎、脑炎、外周神经损伤、喉癌、乳癌、卵巢肿瘤、肝癌、大肠癌、胃癌、肾上腺癌、神经胶质瘤、成胶质细胞瘤、成纤维细胞瘤、神经肉瘤、肺癌、子宫癌、淋巴瘤、前列腺癌、黑素瘤、睾丸肿瘤、星形细胞瘤或异位产生激素的肿瘤等的诊断剂，其包括式(I)所示的放射性卤素标记的苯氧基苯胺衍生物作为活性成分。
发明优势
根据本发明，提供了多种用作PBR配体的具有很强亲和性和很高选择性的化合物。此外，可以通过在PBR的外部计数中用放射性卤素核素对具有很强亲和性和很高选择性的PBR配体进行标记，通过包括PET以及SPECT的技术测定活体内的PBR。这样能够进行阿尔茨海默氏病、额颞叶痴呆症、弥漫性Lewy小体病、血管病变、帕金森氏症相关疾病、皮质延髓变性、帕金森氏症、惠廷顿氏舞蹈病、多系统萎缩症、多发性硬化、癫痫症、脑膜炎、脑炎、外周神经损伤、喉癌、乳癌、卵巢肿瘤、肝癌、大肠癌、胃癌、肾上腺癌、神经胶质瘤、成胶质细胞瘤、成纤维细胞瘤、神经肉瘤、肺癌、子宫癌、淋巴瘤、前列腺癌、黑素瘤、睾丸肿瘤、星形细胞瘤或异位产生激素的肿瘤等的早期诊断。此外，本发明的化合物可用作上述疾病的预防和治疗药物。
附图说明
图1是将[131I]2IDAA1106给予大鼠后30分钟内脑的离体放射自显影照片。
图2是将[131I]2IDAA1106给予大鼠后30分钟内脑的离体放射自显影照片。
具体实施方式
在本发明中，卤原子是氟原子、氯原子、溴原子或碘原子；优选其为氟原子、碘原子或溴原子；更优选其为氟原子或碘原子。
在本发明中，具有1-10个碳原子的烷基是指线性、支链或环状烷基；而且，例如，其包括甲基、乙基、丙基、异丙基、环丙基、丁基、异丁基、环丁基、环丙基甲基、戊基、异戊基、环戊基、环丁基甲基、1-乙基丙基、己基、异己基、环己基、环戊基甲基、1-乙基丁基、庚基、异庚基、环己基甲基、辛基、壬基和癸基。
在本发明中，具有1-10个碳原子的取代烷基是指被“羟基、烷酰氧基、烷酰基、烷氧基、卤原子、叠氮基、氨基、羧基”取代的烷基；并且，例如，其包括羟甲基、乙酰氧基甲基、甲氧基甲基、氯甲基、三氟甲基、叠氮甲基、氨基甲基、二甲基氨基甲基和吡咯烷甲基。
在本发明中，具有1-10个碳原子的烷氧基是指线性、支链或环状烷氧基；而且，例如，其包括甲氧基、乙氧基、丙氧基、异丙氧基、丁氧基、异丁氧基、环丙基甲氧基、戊氧基、异戊氧基、己氧基、庚氧基、辛氧基、壬氧基和癸氧基。
在本发明中，取代苯基是指被1-3个选自如下基团的基团取代的苯基：具有1-10个碳原子的烷基、具有1-10个碳原子的被“卤原子、羟基、具有1-10个碳原子的烷酰氧基、羧基或烷氧基羰基”取代的烷基、具有2-10个碳原子的烯基、具有1-10个碳原子的烷氧基、具有1-10个碳原子的烷基硫代基(alkylthio group)、式-O-Z-R4所示的基团(其中Z代表具有1-10个碳原子的支链或直链烯基，R4代表氨基、被1或2个具有1-7个碳原子的烷基取代的氨基、具有2-7个碳原子的环状氨基、羟基、羧基或烷氧基羰基)、具有2-10个碳原子的烷酰基或其缩酮、甲酰基或其缩醛、羧基、具有2-10个碳原子的烷氧基羰基、氨基甲酰基、其中氮原子被1或2个具有1-10个碳原子的烷基取代的氨基甲酰基、氨基磺酰基、其中氮原子被1或2个具有1-10个碳原子的烷基取代的氨基磺酰基、卤原子和硝基；其包括，例如，2-甲基苯基、2-丙基苯基、2-异丙基苯基、2-环戊基苯基、2-(1-羟乙基)苯基、2-羧基甲基苯基、2-甲氧基羰基苯基、2-乙烯基苯基、2-甲氧基苯基、3-甲氧基苯基、4-甲氧基苯基、2-乙氧基苯基、2-己氧基苯基、2-异丙氧基苯基、2-环戊氧基苯基、2，5-二甲氧基苯基、2，4，6-三甲氧基苯基、4-甲基硫代苯基(4-methylthiophenyl group)、2-异丙基硫代苯基、4-环己基硫代苯基、2-(2-二甲基氨基乙氧基)苯基、2-(2-羟基乙氧基)苯基、2-羧基甲氧基苯基、2-甲氧基羰基甲氧基苯基、2-乙酰基苯基、2-(2-甲基-1，3-二氧戊环-2-基)苯基、2-甲酰基苯基、2-(1，3-二氧戊环-2-基)苯基、2-羧基苯基、2-(N-甲基氨基羰基)苯基、2-(N，N-二甲基氨基羰基)苯基、2-氨基羰基苯基、2-氨基磺酰基苯基、4-氨基磺酰基苯基、2-甲基氨基磺酰基苯基、2-二甲基氨基磺酰基苯基、2-氟苯基、3-氟苯基、4-氟苯基、2-氯苯基、3-氯苯基、4-氯苯基、2-溴苯基、3-溴苯基、4-溴苯基、2，4-二氟苯基、2-硝基苯基、2-氨基苯基、2-吡咯烷苯基、和4-二甲基氨基苯基。
在本发明中，式NR2(R3)所示的4-10元环状氨基是指可以含有氮原子或氧原子的环状氨基；其包括，例如，吡咯烷基、哌啶基、哌嗪基、N-甲基哌嗪基、吗啉基。
本发明的化合物可以通过如下所示的方法，从以JP 11-171844A所述的相同的方法制备的化合物来制备(在反应式中，X1、X2和R1所指与上文相同)。
[式2]
因此，可以将上式代表的具有各种非放射性卤原子的N-(2-苄氧基-5-烷氧基苄基)-N-(苯氧基苯基)酰胺化合物与钯复合物和有机锡化合物反应，从而将非放射性卤原子用有机锡取代基取代，然后与各种放射性卤试剂反应，得到用卤原子标记的苯氧基苯胺衍生物。在此，X1、X2、X3和X4中的至少一个代表选自121I、123I、124I、125I、131I、75Br、76Br、77Br和34mCl的放射性卤原子。
以下通过操作实施例和实验实施例对本发明进行更详细的说明。
实施例
(实施例1)
制备[131I]-N-(2，5-二甲氧基苄基)-N-(5-碘-2-苯氧基苯基)乙酰胺(下文中称为[131I]-1IDAA1106)
1-1)将N-(2，5-二甲氧基苄基)-N-(5-溴-2-苯氧基苯基)乙酰胺(510mg，1.12mmol)溶解在甲苯中，并用六丁基二锡(IV)和二氯二(三苯基膦)钯(0)回流4天。除去甲苯后，反应产物通过硅胶柱层析(通过己烷∶乙酸乙酯＝1∶4洗脱)提纯，得到320mg(43％)N-(2，5-二甲氧基苄基)-N-(5-三丁基甲锡烷基-2-苯氧基苯基)乙酰胺。
FABMS C36H48FNO3Sn(m/z)680.5(m++1)
向N-(2，5-二甲氧基苄基)-N-(5-三丁基甲锡烷基-2-苯氧基苯基)乙酰胺(55mg，0.083mmol)的氯仿溶液中加入100mg固体碘，生成的反应液在室温下搅拌1小时，然后向反应液中加入饱和硫代硫酸钠水溶液，直至反应液变为无色。分离有机层，用饱和盐水溶液洗涤，并用无水硫酸镁干燥。将减压蒸发溶剂得到的粗产品通过硅胶柱层析(通过己烷∶乙酸乙酯＝1∶4洗脱)提纯，得到32mg(77％)题述化合物。
1-2)将100μL乙酸/30％过氧化氢(3/1)加入到N-(2-三丁基甲锡烷基-5-甲氧基苄基)-N-(5-氟-2-苯氧基苯基)乙酰胺(0.1mg)的乙酸乙酯(100μL)中并混合。向混合物中加入[131I]NaI(0.1mCi)，静置1分钟。反应完成后，将反应混合物注射到反相半制备性HPLC(YMC J’sphere ODS-H80柱，10mmID×250mm)中。在4mL/min的流速下使用CH3CN/H2O(9/1)作为流动相，得到[131I]1IDAA1106的馏分。减压蒸馏从该馏分中除去溶剂，残余物溶解在生理盐水(1mL)中，然后使其通过0.22μm Millipore滤器，成功地得到[131I]1IDAA1106(0.091mCi)。
(实施例2)
制备N-(2-[131I]碘-甲氧基苄基)-N-(5-氟-2-苯氧基苯基)乙酰胺(下文中称为[131I]-2IDAA1106)
将100μL乙酸/30％过氧化氢(3/1)加入到N-(2-三丁基甲锡烷基-5-甲氧基苄基)-N-(5-氟-2-苯氧基苯基)乙酰胺(0.1mg)的乙酸乙酯(100μL)溶液中并混合。向其中加入[131I]NaI(0.1mCi)，静置1分钟。反应完成后，将反应混合物注射到反相半制备性HPLC(YMC J’sphereODS-H80柱，10mmID×250mm)中。在4mL/min的流速下使用CH3CN/H2O(9/1)作为流动相，得到[131I]1IDAA1106的馏分。减压蒸馏从该馏分中除去溶剂，残余物溶解在生理盐水(1mL)中，然后使其通过0.22μm Millipore滤器，成功地得到[131I]2IDAA1106(0.095mCi)。
(实验实施例)
离体放射自显影
图1和图2显示了将[131I]2IDAA1106给予大鼠后30分钟内脑的离体放射自显影照片。如图1所示，[131I]2IDAA1106显示出相对很高的脑渗透特性，符合放射性配体的基本要求。嗅球、脉络丛和小脑处存在相对很高的放射性分布，这种分布图谱与外周苯二氮卓类受体的脑内分布相一致。此外，如图2所示，将DAA1106和[131I]2IDAA1106同时给药时，整个脑内的放射性分布降低。具体来说，嗅球、脉络丛和小脑处的放射性水平显著降低，等于或小于图1的20％。这些事实说明，[131I]2IDAA1106是对外周苯二氮卓类受体有特异性的放射性配体。此外，表明[131I]2IDAA1106可以对外周苯二氮卓类受体进行成像。
下面，显示了引入11C的具有烷氧基的本发明化合物的合成。
DAA1106(2)：R＝CH3 DAA1097(3)：R＝CH(CH3)2
[11C]DAA1106([11C]2)：R＝11CH3 [11C]3：R＝11CH(CH3)2
[11C]7：R＝11CH2CH3
[11C]8：R＝11CH3
DAA1097(3)：R＝CH(CH3)2
[11C]3：R＝11CH(CH3)2
[11C]7：R＝11CH2CH3
[11C]8：R＝11CH3
9：R＝OH
(实施例3)
N-(4-氯-2-苯氧基苯基)-N-(2-[2-11C]异丙氧基苄基)乙酰胺([11C]3)
对含有0.01％氧气的超高纯氮气(1.5MPa)进行来自回旋加速器的18.5MeV质子的辐射，通过14N(p，α)11C核反应产生无载体[11C]CO2。
辐射之后，通过N2(50mL/min)从气体靶标收集的[11C]CO2，并浓缩，直至在液N2中冷却至-150℃的不锈钢线圈中整个线圈中的放射性达到稳定状态。当升温时排出浓缩的[11C]CO2，使干燥N2(2mL/min)在-5℃下流入含有CH3MgBr的回路中。当完成放射性的转移后，停止N2流，然后将该回路在25℃下保持5分钟，以进行格利雅(Grignard)反应。随后，使LiAlH4的THF溶液(0.2M，500μL)通过回路，将反应混合物移动至180℃的加热反应器1分钟。反应器在50-60℃下冷却后，向该反应器加入HI水溶液(57％，800μL)。反应混合物加热至180℃，生成的放射性馏分用N2(50mL/min)吹扫，并在室温下引入至Porapak(商品名)柱的入口。N2流持续3分钟，直至柱入口中的放射性水平变稳定。当该柱被加热时(加热速率：15℃/30秒)，[11C]10开始在6分钟内丛柱出口流出，其被收集到含有无水DMF(1mL)的罐中。然后该[11C]CO2被用于与格氏试剂MeMgBr的反应中，然后通过气相色谱分离，得到放射化学纯度＞95％的[11C]10(3.7-4.4GBq，n＝3)。
将9(1.0mg)、[11C]10(3.0-3.2GBq)和NaH(7μL，0.5g/20mLDMF)的DMF悬液加热至130℃，并将其保持10分钟。加入CH3CN/H2O(90-10，0.5mL)使含有[11C]3的反应混合物淬火，然后使其通过装在JASCO HPLC系统中的半分馏柱(内径10mm×250mm，CAPCELLPAK C18，SHISEIDO)。在该柱上使用CH3CN/H2O进行洗脱，流速为5.0mL/min，将所需的馏分(tR＝8.8min)收集在烧瓶中。将溶剂在90℃下丛烧瓶中减压蒸去后，残余物收集在10mL无菌盐水溶液中。使[11C]3的盐水溶液通过无菌0.22μm滤器，进入无菌瓶中。在合成结束时，得到放射化学纯度＞98％的[11C]3(180-310MBq，n＝3)。
(实施例4)
N-(4-氯-2-苯氧基苯基)-N-(2-[2-11C]乙氧基苄基)乙酰胺([11C]7)
通过进行CH3MgBr与[11C]CO2的反应，在合成结束时，得到放射化学纯度＞95％的[11C]11(3.9-5.3GBq，n＝3)。
将9(1.0mg)、[11C]11(3.0-3.2GBq)和NaH(7μL，0.5g/20mLDMF)在DMF(1mL)中的悬液加热至50℃，并将其保持5分钟。反应混合物通过上述使用的相同柱子进行提纯，不同之处在于使用CH3CN/H2O(80/20)，得到所需的放射性馏分(tR＝8.1min)。通过如在[11C]3上进行的相同方法处理之后，在合成结束时，得到放射化学纯度＞98％的[11C]7(300-350MBq，n＝3)。
(实施例5)
N-(4-氯-2-苯氧基苯基)-N-(2-[2-11C]甲氧基苄基)乙酰胺([11C]8)[11C]12的制备以及随后[11C]9甲基化为[11C]8在自动合成仪上进行。将由此形成的[11C]12蒸馏，通过烧碱石棉和P2O5柱，并收集在含有9(1.0mg)、NaH(7μL，0.5g/20mL DMF)和DMF(1mL)的容器中，在-15至-20℃下保持1.5分钟。然后将反应容器加热至30℃，保持5分钟。反应混合物通过上述使用的相同柱子进行提纯，不同之处在于使用CH3CN/H2O(70-30)，得到所需的放射性馏分(tR＝9.5min)。通过如在[11C]3上进行的相同方法处理之后，在合成结束时，得到放射化学纯度＞98％的[11C]8(1.0-1.3GBq，n＝3)。
(实施例6)
N-(5-氟-2-苯氧基苯基)-N-(2-[11C]甲氧基-5-甲氧基苄基)乙酰胺([11C]2)
通过与实施例5中所用方法类似的方法，得到了题述的化合物。
工业应用性
本发明的化合物可以用作多种疾病如阿尔茨海默氏病、额颞叶痴呆症、弥漫性Lewy小体病、血管病变、帕金森氏症相关疾病、皮质延髓变性、帕金森氏症、惠廷顿氏舞蹈病、多系统萎缩症、多发性硬化、癫痫症、脑膜炎、脑炎、外周神经损伤、喉癌、乳癌、卵巢肿瘤、肝癌、大肠癌、胃癌、肾上腺癌、神经胶质瘤、成胶质细胞瘤、成纤维细胞瘤、神经肉瘤、肺癌、子宫癌、淋巴瘤、前列腺癌、黑素瘤、睾丸肿瘤、星形细胞瘤和异位产生激素的肿瘤的早期诊断剂，也可用作上述疾病的预防和治疗药物。
Claims (5)
1.一种式(I)所示的放射性卤素标记的苯氧基苯胺衍生物：
[式1]
其中，R1代表氢原子、具有1-10个碳原子的取代或未取代烷基、具有1-10个碳原子的烷氧基、取代或未取代苯基、式-NR2(R3)所示的基团，其中R2和R3相同或者不同，并代表氢原子、具有1-10个碳原子的烷基，或者与相邻的氮原子一起形成4-10元环状氨基，且X1、X2、X3和X4相同或不同，各自代表氢原子、具有1-5个碳原子的烷基、具有1-5个碳原子的烷氧基、苯氧基、三氟甲基、氨基甲酰基、氨基磺酰基、卤原子、具有1-5个碳原子的用11C或选自121I、123I、124I、125I、131I、75Br、76Br、77Br和34mCl的放射性卤原子标记的烷氧基，其条件是X1、X2、X3和X4中的至少一个代表具有1-5个碳原子的用11C或选自121I、123I、124I、125I、131I、75Br、76Br、77Br和34mCl的放射性卤原子标记的烷氧基。
2.根据权利要求1所述的放射性卤素标记的苯氧基苯胺衍生物，其中，R1代表氢原子、具有1-10个碳原子的取代或未取代烷基，且X1、X2、X3和X4相同或不同，各自代表氢原子、具有1-5个碳原子的烷氧基、卤原子或具有1-5个碳原子的用11C或选自121I、123I、124I、125I、131I、75Br、76Br、77Br和34mCl的放射性卤原子标记的烷氧基，其条件是X1、X2、X3和X4中的至少一个代表选自121I、123I、124I、125I、131I、75Br、76Br、77Br和34mCl的放射性卤原子。
3.根据权利要求1所述的放射性卤素标记的苯氧基苯胺衍生物，其中
R1代表具有1-10个碳原子的烷基，
X1和X2各自代表具有1-5个碳原子的烷氧基，
X3代表选自121I、123I、124I、125I、131I、75Br、76Br、77Br和34mCl的放射性卤原子，
且X4代表氢原子。
4.根据权利要求1所述的放射性卤素标记的苯氧基苯胺衍生物，其中，
R1代表具有1-10个碳原子的烷基，
X1和X2相同或不同，各自代表具有1-5个碳原子的烷氧基或选自121I、123I、124I、125I、131I、75Br、76Br、77Br和34mCl的放射性卤原子，其条件是X1和X2中的任一个代表选自121I、123I、124I、125I、131I、75Br、76Br、77Br和34mCl的放射性卤原子，
X3代表卤原子，
且X4代表氢原子。
5.一种阿尔茨海默氏病、额颞叶痴呆症、弥漫性Lewy小体病、血管病变、帕金森氏症相关疾病、皮质延髓变性、帕金森氏症、惠廷顿氏舞蹈病、多系统萎缩症、多发性硬化、癫痫症、脑膜炎、脑炎、外周神经损伤、喉癌、乳癌、卵巢肿瘤、肝癌、大肠癌、胃癌、肾上腺癌、神经胶质瘤、成胶质细胞瘤、成纤维细胞瘤、神经肉瘤、肺癌、子宫癌、淋巴瘤、前列腺癌、黑素瘤、睾丸肿瘤、星形细胞瘤或异位产生激素的肿瘤的诊断剂，其包括根据权利要求1-4中任意一项所述的放射性卤素标记的苯氧基苯胺衍生物作为活性成分。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP052527/2005 | 2005-02-28 | ||
| JP2005052527 | 2005-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101133017A true CN101133017A (zh) | 2008-02-27 |
Family
ID=36940944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2005800488048A Pending CN101133017A (zh) | 2005-02-28 | 2005-12-28 | 放射性卤素标记的苯氧基苯胺衍生物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20090234162A1 (zh) |
| EP (1) | EP1854781A1 (zh) |
| JP (1) | JPWO2006092902A1 (zh) |
| KR (1) | KR20070108883A (zh) |
| CN (1) | CN101133017A (zh) |
| AU (1) | AU2005328464B2 (zh) |
| BR (1) | BRPI0520092A2 (zh) |
| CA (1) | CA2599321A1 (zh) |
| IL (1) | IL185333A0 (zh) |
| MX (1) | MX2007010343A (zh) |
| NO (1) | NO20074897L (zh) |
| RU (1) | RU2425824C2 (zh) |
| UA (1) | UA93870C2 (zh) |
| WO (1) | WO2006092902A1 (zh) |
| ZA (1) | ZA200707226B (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107412788A (zh) * | 2012-12-21 | 2017-12-01 | 国立研究开发法人量子科学技术研究开发机构 | 用于对脑内所蓄积的Tau蛋白质进行成像的新的化合物 |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2094625A1 (en) * | 2006-12-21 | 2009-09-02 | Hammersmith Imanet, Ltd | Radiolabelling methods |
| US20100055036A1 (en) * | 2007-03-12 | 2010-03-04 | National Institute of Radiolotgical Sciences | Pet visualization of amyloid-associated neuroinflammation in the brain |
| EP1997515A1 (en) * | 2007-05-30 | 2008-12-03 | Bayer Schering Pharma Aktiengesellschaft | Use of radiolabelled phenyloxyaniline derivatives for imaging diseases associated with peripheral benzodiazepin receptor's activation |
| US20110064662A1 (en) * | 2007-10-31 | 2011-03-17 | Riken | Kit for producing molecular probe for pet screening for drug discovery |
| GB0722779D0 (en) * | 2007-11-20 | 2008-01-02 | Sterix Ltd | Compound |
| GB0904715D0 (en) | 2009-03-19 | 2009-05-06 | Ge Healthcare Ltd | Aryloxyanilide derivataives |
| GB0921967D0 (en) | 2009-12-17 | 2010-02-03 | Ge Healthcare Ltd | Novel Aryloxyanilide Derivatives |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5122361A (en) * | 1989-04-17 | 1992-06-16 | Trustees Of The University Of Pennsylvania | Dopamine receptor ligands and imaging agents |
| US5993777A (en) * | 1993-05-06 | 1999-11-30 | Research Corporation Technologies, Inc. | Benzamide compounds for cancer imaging and therapy |
| JP4302207B2 (ja) * | 1997-08-04 | 2009-07-22 | 大正製薬株式会社 | アリールオキシアニリン誘導体 |
| WO1999006353A1 (fr) * | 1997-08-04 | 1999-02-11 | Taisho Pharmaceutical Co., Ltd. | Derives aryloxyaniline |
| US6843979B2 (en) * | 1999-04-26 | 2005-01-18 | Emory University | 4-haloethenylphenyl tropane:serotonin transporter imaging agents |
| CA2369663A1 (en) * | 1999-04-26 | 2000-11-02 | Emory University | 4-fluoroalkyl-3-halophenyl nortropanes |
| US6870069B2 (en) * | 2003-01-10 | 2005-03-22 | National Institute Of Radiological Sciences | Phenyloxyaniline derivatives |
-
2005
- 2005-12-28 KR KR1020077019539A patent/KR20070108883A/ko not_active Application Discontinuation
- 2005-12-28 EP EP05822458A patent/EP1854781A1/en not_active Withdrawn
- 2005-12-28 AU AU2005328464A patent/AU2005328464B2/en not_active Ceased
- 2005-12-28 CA CA002599321A patent/CA2599321A1/en not_active Abandoned
- 2005-12-28 ZA ZA200707226A patent/ZA200707226B/xx unknown
- 2005-12-28 US US11/884,763 patent/US20090234162A1/en not_active Abandoned
- 2005-12-28 MX MX2007010343A patent/MX2007010343A/es not_active Application Discontinuation
- 2005-12-28 CN CNA2005800488048A patent/CN101133017A/zh active Pending
- 2005-12-28 UA UAA200710682A patent/UA93870C2/ru unknown
- 2005-12-28 BR BRPI0520092-0A patent/BRPI0520092A2/pt not_active IP Right Cessation
- 2005-12-28 RU RU2007135882/04A patent/RU2425824C2/ru not_active IP Right Cessation
- 2005-12-28 WO PCT/JP2005/024075 patent/WO2006092902A1/ja active Application Filing
- 2005-12-28 JP JP2007505812A patent/JPWO2006092902A1/ja active Pending
-
2007
- 2007-08-16 IL IL185333A patent/IL185333A0/en unknown
- 2007-09-26 NO NO20074897A patent/NO20074897L/no not_active Application Discontinuation
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107412788A (zh) * | 2012-12-21 | 2017-12-01 | 国立研究开发法人量子科学技术研究开发机构 | 用于对脑内所蓄积的Tau蛋白质进行成像的新的化合物 |
| CN107412788B (zh) * | 2012-12-21 | 2021-06-18 | 国立研究开发法人量子科学技术研究开发机构 | 用于对脑内所蓄积的Tau蛋白质进行成像的新的化合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20070108883A (ko) | 2007-11-13 |
| RU2425824C2 (ru) | 2011-08-10 |
| US20090234162A1 (en) | 2009-09-17 |
| CA2599321A1 (en) | 2006-09-08 |
| AU2005328464B2 (en) | 2011-02-24 |
| WO2006092902A1 (ja) | 2006-09-08 |
| UA93870C2 (ru) | 2011-03-25 |
| BRPI0520092A2 (pt) | 2009-08-18 |
| AU2005328464A1 (en) | 2006-09-08 |
| ZA200707226B (en) | 2009-09-30 |
| NO20074897L (no) | 2007-11-21 |
| JPWO2006092902A1 (ja) | 2008-08-07 |
| EP1854781A1 (en) | 2007-11-14 |
| RU2007135882A (ru) | 2009-04-10 |
| IL185333A0 (en) | 2008-02-09 |
| MX2007010343A (es) | 2008-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101133017A (zh) | 放射性卤素标记的苯氧基苯胺衍生物 | |
| JP5922207B2 (ja) | 灌流造影を含む適用のための造影剤 | |
| CN102272100B (zh) | 用于抑制psma的锝-和铼-双(杂芳基)络合物及其使用方法 | |
| JPH075527B2 (ja) | 二官能性ｄｔｐａ型リガンド | |
| CN105229008A (zh) | 作为选择性NK-3受体拮抗剂的新型N-酰基-(3-取代)-(8-取代)-5,6-二氢-[1,2,4]三唑并[4,3-a]吡嗪、药物组合物、用于NK-3受体介导的病症的方法 | |
| JP2011207901A (ja) | 腫瘍画像化のためのアミノ酸アナログ | |
| JPH11514368A (ja) | ドーパミン及びセロトニン輸送体リガンド並びにイメージング剤 | |
| CN104024232A (zh) | 新吡嗪衍生物 | |
| Moins et al. | Synthesis, characterization and comparative biodistribution study of a new series of p-iodine-125 benzamides as potential melanoma imaging agents | |
| KR100745445B1 (ko) | 종양 영상화 화합물 | |
| EP2139481B1 (en) | 1-[(2'-substituted)-piperazin-1'-yl]-isoquinolines as norepinephrine transporter inhibitor therapeutics and positron emission tomography imaging agents | |
| JP2002525325A (ja) | 放射標識化ニューロキニン−１受容体拮抗薬 | |
| Wang et al. | Synthesis and biological evaluation of 18F labeled fluoro-oligo-ethoxylated 4-benzylpiperazine derivatives for sigma-1 receptor imaging | |
| CA2454228C (en) | Radiolabeled neuropeptide y y5 receptor antagonists | |
| Wadsak et al. | Preparation and first evaluation of [18F] FE@ SUPPY: a new PET tracer for the adenosine A3 receptor | |
| EP1923382A1 (de) | [F-18] markierte L-Glutaminsäure, [F-18] markiertes Glutamin, ihre Derivate und ihre Verwendung sowie Verfahren zu ihrer Herstellung | |
| Li et al. | Synthesis and biological evaluation of novel 4-benzylpiperazine ligands for sigma-1 receptor imaging | |
| Mori et al. | Comparison between [18F] fluorination and [18F] fluoroethylation reactions for the synthesis of the PDE10A PET radiotracer [18F] MNI-659 | |
| DE102004011720B4 (de) | Radiohalogenierte Benzamidderivate und deren Verwendung in der Tumordiagnostik und Tumortherapie | |
| Pichika et al. | Nicotinic α4β2 receptor imaging agents. Part IV. Synthesis and biological evaluation of 3-(2-(S)-3, 4-dehydropyrrolinyl methoxy)-5-(3′-18F-fluoropropyl) pyridine (18F-Nifrolene) using PET | |
| Kimura et al. | Synthesis and biological evaluation of Tc-99m-cyclopentadienyltricarbonyl-technetium-labeled A-85380: An imaging probe for single-photon emission computed tomography investigation of nicotinic acetylcholine receptors in the brain | |
| Mann et al. | Receptor mapping using methoxy phenyl piperazine derivative: Preclinical PET imaging | |
| CN113549052B (zh) | 4-苯基-1-（吡啶-4-基甲基）吡咯烷-2-酮衍生物及其制备方法和应用 | |
| CN102186844B (zh) | 放射性标记的甘氨酸1转运蛋白抑制剂 | |
| Guo et al. | Synthesis and biological evaluation of one novel technetium-99m-labeled nitroquipazine derivative as an imaging agent for serotonin transporter |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1115115 Country of ref document: HK |
|
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20080227 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1115115 Country of ref document: HK |